This study is conducted in Europe. The aim of this study is to evaluate efficacy and safety of insulin detemir (Levemir®) used as basal insulin on the glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2 diabetes treated with insulin NPH under normal clinical practice conditions in Slovakia.
Study Type
OBSERVATIONAL
Enrollment
631
Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
Novo Nordisk Investigational Site
Bratislava, Slovakia
Change in HbA1c (glycosylated haemoglobin)
Change in weight
Change in fasting plasma glucose (FPG)
Change in 4-points glucose profiles
Change in lipid profile
Number of hypoglycaemic events
Number of adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.